Medical & Surgical Specialists, LLC

Galesburg, Illinois 61401

0 studies enrolling now · 27 studies all time

What they study most

Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Lung Cancer, Metastatic Breast Cancer, Metastatic Prostate Cancer, Myelodysplastic Syndromes, Non Small Cell Lung Carcinoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Prostate Cancer

Studies at this site

• Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse — Stopped early
• BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma — Completed
• Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer — Completed
• Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer — Stopped early
• Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes — Stopped early
• A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer — Stopped early
• Sutent + Taxol for Advanced Esophageal Cancer — Completed
• Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer — Completed
• A Biological Sample Collection Protocol of Women With and Without Breast Cancer — Completed
• Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer — Completed
• Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer — Stopped early
• Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy — Stopped early
• Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas — Completed
• Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer — Stopped early
• Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer — Completed
• Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer — Completed
• Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer — Stopped early
• Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer — Completed
• Lonafarnib in Metastatic Breast Cancer — Stopped early
• Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer — Completed
• Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies — Completed
• Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer — Completed
• Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer — Completed
• Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer — Stopped early
• A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer — Completed
• Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer — Stopped early
• Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer — Completed